Sugi Predict

Sugi Predict / Compounds / SCHEMBL940704

SCHEMBL940704

SCHEMBL940704

O=C(Cl)c1ccc(F)c(S(=O)(=O)Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTK2B Q14289 2/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ CES2 O00748 1/20 0.39
▸ CES1 P23141 1/20 0.39
▸ MAPT P10636 7/20 0.38
▸ TP53 P04637 6/20 0.38
▸ ACLY P53396 2/20 0.36
▸ LMNA P02545 6/20 0.36
▸ POLB P06746 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ ALOX15 P16050 1/20 0.34
▸ TSHR P16473 2/20 0.34
▸ KAT6A Q92794 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5030349 0.87 PTK2B (0.44) PTK2BSMN1; SMN2CES2CES1MAPT
SCHEMBL19862657 0.85 CES2 (0.39) PTK2BSMN1; SMN2CES2CES1LMNA
SCHEMBL29403183 0.85 PTK2B (0.58) PTK2BSMN1; SMN2ACLYLMNAPOLB
SCHEMBL940353 0.85 PTK2B (0.58) PTK2BSMN1; SMN2ACLYLMNAPOLB
SCHEMBL11597913 0.84 PTK2B (0.42) PTK2BSMN1; SMN2CES2CES1MAPT
SCHEMBL11169516 0.84 PTK2B (0.42) PTK2BSMN1; SMN2CES2CES1MAPT
SCHEMBL9900899 0.84 PTK2B (0.42) PTK2BSMN1; SMN2CES2CES1MAPT
SCHEMBL18948550 0.81 PTK2B (0.40) PTK2BSMN1; SMN2MAPTTP53LMNA
SCHEMBL19475371 0.80 ACLY (0.51) PTK2BSMN1; SMN2MAPTACLYPOLB
SCHEMBL30695462 0.80 ACLY (0.51) PTK2BSMN1; SMN2MAPTACLYPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210276967-A1 INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2021-09-09 — — US disclosed
US-20210276967-A1 INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2021-09-09 — — US disclosed
EP-2890375-B1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2021-07-28 — — EP disclosed
CN-112912368-A Inhibitors of hepatitis B virus 圣拉斐尔医院有限公司 2021-06-04 — — CN disclosed
EP-3823957-A1 INHIBITORS OF HEPATITIS B VIRUS Ospedale San Raffaele S.r.l. (IT) 2021-05-26 — — EP disclosed
US-10995064-B2 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B JANSSEN SCIENCES IRELAND UC (IE) 2021-05-04 — — US disclosed
US-20210024462-A1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) 2021-01-28 — — US disclosed
US-20200255373-A1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B JANSSEN SCIENCES IRELAND UC (IE) 2020-08-13 — — US disclosed
US-10682419-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2020-06-16 — — US disclosed
US-10682419-B2 Prodrugs of peptide epoxy ketone protease inhibitors ONYX THERAPEUTICS, INC. (US) 2020-06-16 — — US disclosed
US-20110014186-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2011-01-20 — — US disclosed
US-20110014186-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2011-01-20 — — US disclosed
US-20110014186-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2011-01-20 — — US disclosed
EP-2268612-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS Novartis AG (CH) 2011-01-05 — — EP disclosed
CN-101142193-B 1, 3-propanedione derivative or salt thereof ASTELLAS PHARMA INC 2010-12-29 — — CN disclosed
WO-2009118292-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2009-10-01 — — WO disclosed
WO-2009118292-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS NOVARTIS AG (CH) 2009-10-01 — — WO disclosed
US-20090181964-A1 Propane-1,3-Dione Derivative or Salt Thereof ASTELLAS PHARMA INC. 2009-07-16 — — US disclosed
CN-101142193-A 1, 3-propanedione derivative or salt thereof ASTELLAS PHARMA INC (JP) 2008-03-12 — — CN disclosed
EP-1864976-A1 PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF Astellas Pharma Inc. (JP) 2007-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181964-A1 Propane-1,3-Dione Derivative or Salt Thereof GNRHR, KISS1R, FSHR PTK2B 1076/4885SMN1; SMN2 1249/4885CES2 4638/4885
US-20110014186-A1 ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS MMP11, MMP10, MMP9 PTK2B 1130/4885SMN1; SMN2 1506/4885CES2 408/4885
US-10682419-B2 Prodrugs of peptide epoxy ketone protease inhibitors PREP, VIP, PEPD PTK2B 2661/4885SMN1; SMN2 4444/4885CES2 153/4885
US-20200255373-A1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B SULT2A1, HCCS, SULT1A1 PTK2B 2861/4885SMN1; SMN2 4600/4885CES2 2524/4885
US-10995064-B2 Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis B SULT2A1, HCCS, SULT1A1 PTK2B 2861/4885SMN1; SMN2 4600/4885CES2 2524/4885
US-20210276967-A1 INHIBITORS OF HEPATITIS B VIRUS HAVCR2, SLC10A1, HDGF PTK2B 3080/4885SMN1; SMN2 4877/4885CES2 1065/4885
US-20210024462-A1 SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B SULT2A1, HCCS, SULT1A1 PTK2B 2861/4885SMN1; SMN2 4600/4885CES2 2524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.